"Cleaning memory" twice in three years, Shanghai linked to the Internet and kicked out more than 2,000 drugs!

Pharmaceutical Network on May 19th, Shanghai Sunshine Procurement Network issued two consecutive announcements, respectively, to close the procurement status of medical insurance drugs and self-funded drugs without procurement records, this time involving 871 out-of-pocket drugs and 1310 medical insurance drugs, including some star varietiesIndustry insiders speculate that these drugs do not have procurement records, one is that pharmaceutical companies have multiple specifications at the same time, the second is the price of the network is too low, pharmaceutical companies give up sales, and the third is that pharmaceutical companies have carried out supplementary packaging, resulting in some packaging has not been purchased by the hospitalIf there is a real demand for procurement in a medical institution, the production enterprise may re-declare it in accordance with the new application drug rulesIn June 2017, Shanghai Sunshine Pharmaceutical Procurement Network closed its 2016 non-purchase recorded drug procurement status, a total of 8,763 drugs suspended from the internet"
there have been industry insiders so said: China's pharmaceutical market how many drugs can meet the demand for clinical drugs, there is no need for nearly 200,000 approvals, large but not strong, on the contrary, breeding many problemsOnly from the Shanghai Sunshine Procurement Network in three years of the two "clearing memory" operation, the total closure of 10944specifications of the transaction status, it can be seen that the "home base" thick, the whole country is also close2020, the state will comprehensively promote centralized drug procurement and continue to promote the evaluation of drug consistencyLooking back over the past decade, the process of China's generic drugs has made rapid progress, is the era of the outbreak of theand quantity of generic drugs, but also the quality of generic drugs and the price of the period of fierce criticismContinue to look forward to the current reform not only to achievecontrol fees, but also to raise the quality of generic drugs, to protect the competition of generic drugsShanghai Sunshine Procurement Network on the zombie drug two centralized "de-listing", there are two characteristics: First, not only for pharmaceutical catalog drugs, is a larger than the medical insurance catalog procurement of the joint management measures, of great significance; In this paper, we take a different approach, from the harsh Shanghai experience to find the light that generic drugs should seeFirst to cite a combat example: Commander Suyu commanded the Battle of su-China seven battles, the first war Xuantai, in addition to the Shoutai Xing Qingyun Temple, a battalion, the Kuomintang army 83 division 3000 people were all killedThe 49th Division of the Kuomintang Army tried to take advantage of Huaye's main force in Taixing, and entered the occupationHowever, Taixing's Huaye is just a suspect, in fact, the main force has long since withdrawn and ready to ambush this example reveals us: from the country to the local a series of volume procurement gradually hit the overall market size of generic drugs local, the purpose is not to break up the generic drug local market The use of comprehensive policies to guide the market to reform and continue to develop, is the Shanghai Sunshine Procurement Network this approach is an expectation Eliminating inefficient, zombie drugs is fission, adding code to focus on active drugs is fusion China's pharmaceutical market absolutely rely on generic drugs to fill the vast majority of physician prescriptions, which is from the international comparative experience of the inevitable conclusion And because China's medical science and technology transformation and progress takes time, China's economic and social development of the national conditions of people's livelihood needs time, we must need a large and strong generic drug market, a series of review series of generic drugs, price control policy must fight without breaking "de-listing" 10,944 drug specifications, the remaining portion still includes a large number of generic drugs, between them, between them and the adaptation of similar categories of drugs, the competition under the rules of the new medical reform will be more active In the U.S market, the amount of generic prescriptions accounted for 90%, the amount of 20%, generic drugs in China's market performance will be very eye-catching, and mainly rely on domestic generic drugs " In the past decade, China's generic drug industry has grown rapidly In 2017, China's generic drug market reached 500 billion yuan, according to the China Pharmaceutical Industry Information Center estimates that by 2020 China's generic drug market size can exceed the trillion mark Public remain the main battleground for Chinese medicine It is widely believed that 90% of generic drugs will be out of the market in the future, the concentration of the generic sand industry will be further strengthened, and generic drugs that have not passed a consistent evaluation may also be the first to be eliminated "
Shanghai Sunshine Network has so many online drug specifications in 2019 no transaction spree, the specific reasons for the product has stopped production, the specific reasonis: the seller does not want to deal or the buyer does not want to deal, the conclusion is complex, bitter The "de-listing" measure sedats to attract the attention of all parties to the normal trading status of the drug specifications of the internet, and has improved the seriousness and effectiveness of the procurement management of the network pharmaceutical companies regardless of size, in front of the sun procurement network to see whether there are specific product rules or not to strive to achieve sales Well-known pharmaceutical companies often large-scale production, varieties and product regulations, and cost control is superior, pharmaceutical representative team, has also been considered in the generic drug market shuffle to occupy the advantage, but its product regulations are also the cause of this hanging-net drug "de-listing" some well-known varieties in the context of the necessity of medical reform, but also repeatedly appear domestic well-known pharmaceutical companies with gold sales cases, well-known pharmaceutical companies are often no more disciplined than unknown pharmaceutical companies Through the consolidation of hanging-up-net drugs, so that the phenomenon of hanging net is timely eliminated, the competitive space will be easier to observe, guide large and small pharmaceutical companies after recognizing each other's advantages and disadvantages to carry out differential competition, are protected by the rules from the general direction, the conformity evaluation of generic drugs is necessary, but must go through a gradual process Policy requirements are faster than market response, and when promoting band procurement, the merger and competition of pharmaceutical companies follows the law and speed Clinical immediate drug demand is earlier than all consistent evaluation, and competitors compete in quality and efficiency No one can ignore or deliberately resist the development of small and medium-sized pharmaceutical enterprises " In April 2020 alone, Jiangsu, Shenzhen, Beijing and other places have suspended products that have not passed the consistency evaluation From the issuance of notifications from many provinces, the consistency evaluation process is accelerating, there will be a large number of generic drug approvals out of the market has been finalized "
at present, some provinces on the drug network price linkage, requiring pharmaceutical companies to take the lowest transaction price in each provincial platform, rather than the lowest price of the provincial platform If the provisions require the latter price, it is not necessary for the Shanghai Sunshine Procurement Network to personally comb the "de-listing", involving the relevant interests of pharmaceutical companies will take the initiative to adjust or withdraw the price of hanging net, will reduce the error of administrative intervention What would administrative intervention hurt? May be clinically de-shortage drugs and the market should be cleared of drugs, silly is not clear Some drugs that are "delisted" may indeed face a shutdown, leaving the clinic short of good drugs and requiring policy support to resume production In this regard, it is recommended to open a fast-track channel for the relevant pharmaceutical companies to appeal and seek assistance The times a grain of sand falling individualbody is a mountain, pull the storm in both down cooperate with this work, it is recommended to carry out daily, extensive, well-targeted psychoeconomic analysis at the same time Please do not accept the administrative decision of the internet drug specifications do not accept the war, please know its consequences so the drug specifications quietly go away It is also suggested that Shanghai will "de-list" product rules to remind other alliance platforms across regions in a timely manner, to explore multi-dimensional concernand and research beyond price linkage.